Aiforia Technologies Oyj (HEL:AIFORIA)
Finland · Delayed Price · Currency is EUR | Market Cap | 66.90M -41.5% |
| Revenue (ttm) | 3.54M +23.9% |
| Net Income | -12.67M |
| EPS | -0.41 |
| Shares Out | 33.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,358 |
| Average Volume | 53,190 |
| Open | 1.948 |
| Previous Close | 1.938 |
| Day's Range | 1.948 - 2.130 |
| 52-Week Range | 1.560 - 3.730 |
| Beta | 0.14 |
| RSI | 58.67 |
| Earnings Date | Aug 28, 2026 |
About Aiforia Technologies Oyj
Aiforia Technologies Oyj, together with its subsidiary, Aiforia Inc., provides AI-based image analysis software used in clinical, preclinical, and academic laboratories to pathologists and researchers in Finland, rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer; CE-IVD marked Aiforia clinical suite viewer for the clinical pathology... [Read more]
Financial Performance
In 2025, Aiforia Technologies Oyj's revenue was 3.54 million, an increase of 23.95% compared to the previous year's 2.85 million. Losses were -12.67 million, 6.01% more than in 2024.
Financial StatementsNews
Aiforia Technologies PLC (STU:L6J) Full Year 2025 Earnings Call Highlights: Strong Clinical ...
Aiforia Technologies PLC (STU:L6J) Full Year 2025 Earnings Call Highlights: Strong Clinical Growth and Strategic Partnerships
Aiforia Technologies Oyj Earnings Call Transcript: Q4 2025
Revenue grew 24% in 2025, with clinical sector up 68% year-over-year and accelerating in H2. Investments in technology and regulatory compliance drove portfolio expansion, while recurring revenue and major contracts in Europe and the U.S. support scale-up ambitions.
Aiforia Technologies Oyj Earnings Call Transcript: Q2 2025
Order book grew 58% year-over-year, with clinical revenue up 60% and major European customer wins. Revenue was flat overall due to timing of deliveries, but strong pipeline and regulatory progress position the company for accelerated growth in H2 and beyond.
Aiforia Technologies Oyj Earnings Call Transcript: Q4 2024
Order book and revenue grew sharply, driven by clinical market expansion and major European contracts. EBITDA improved, cash reserves remain strong, and break-even is targeted by year-end 2024. Regulatory progress and new AI models support further growth.
Aiforia Technologies Oyj Earnings Call Transcript: Q2 2024
Revenue grew 43% year-over-year, driven by major clinical wins in Europe and a growing order book. Profitability is targeted for 2027, with strong cash reserves and a focus on scaling delivery and expanding key accounts.